Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 12/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623123 | 0.92 | GRM5 (0.43) | CSNK1ECSNK1DABL1EGFRSRC | |
| SCHEMBL26645904 | 0.87 | CSNK1E (0.55) | CSNK1ECSNK1D | |
| SCHEMBL30622835 | 0.86 | CSNK1E (0.44) | CSNK1ECSNK1DABL1EGFRSRC | |
| SCHEMBL26645379 | 0.86 | CSNK1E (0.44) | CSNK1ECSNK1DABL1EGFRSRC | |
| SCHEMBL17129177 | 0.81 | CSNK1D (0.51) | CSNK1ECSNK1DUSP30 | |
| SCHEMBL26645726 | 0.81 | MEN1 (0.46) | CSNK1ECSNK1DMEN1KMT2A | |
| SCHEMBL17382842 | 0.81 | CSNK1E (0.52) | CSNK1ECSNK1D | |
| SCHEMBL26645256 | 0.80 | MEN1 (0.40) | CSNK1ECSNK1DMEN1KMT2A | |
| SCHEMBL24277111 | 0.79 | CSNK1E (0.41) | CSNK1ECSNK1D | |
| SCHEMBL26645772 | 0.79 | GRM5 (0.51) | ABL1EGFRSRCABL2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |